CD9 RNA levels did not predict outcomes in all TNBC subtypes, but were sufficient to predict a poor outcome in basal-like 2 breast cancer patients, a therapy-resistant subtype (Figure S3D) [37]. This evidence concerns the gene CD9 and breast carcinoma.